Frequently Asked Questions
The market is segmented based on Segmentation By Diagnosis (Edrophonium Test, Blood Test, Repetitive Nerve Stimulation, Single-fiber electromyography (EMG), and Others), Treatment Type (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Plasmapheresis, Autologous Hematopoietic Stem Cell Transplantation (HSCT), Surgery, and Others), Route of Administration (Oral and Parenteral), End Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Myasthenia Gravis Disease Market size was valued at USD 776.39 USD Million in 2023.
The Global Myasthenia Gravis Disease Market is projected to grow at a CAGR of 10.9% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
